Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy
暂无分享,去创建一个
H. Dombret | A. Vekhoff | P. Fenaux | S. de Botton | X. Thomas | M. Elhamri | A. Thiébaut | O. Reman | F. Dreyfus | E. Raffoux | A. Pigneux | C. Pautas | N. Dhédin | M. Michallet | Y. Chelghoum | T. de Revel | P. Travade | A. Guerci | J. Troncy | Qh Le | N. Dhedin
[1] M. Kalaycio,et al. Treatment of refractory and relapsed acute myelogenous leukemia , 2002, Expert review of anticancer therapy.
[2] C. Ries,et al. Autologous stem cell transplantation for advanced acute myeloid leukemia , 2002, Bone Marrow Transplantation.
[3] S. Soignet,et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Buckley,et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.
[5] N. Schmitz,et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). , 2000, Blood.
[6] H. Dombret,et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation , 2000, Leukemia.
[7] R. Herrmann,et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia , 1999, British journal of haematology.
[8] H. Dombret,et al. Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial) , 1999, Leukemia.
[9] N. Russell,et al. Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG , 1999, Leukemia.
[10] F. Appelbaum,et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. , 1998, The New England journal of medicine.
[11] N. Gorin. Autologous stem cell transplantation in acute myelocytic leukemia. , 1998, Blood.
[12] Keith Wheatley,et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.
[13] P. Hurteloup,et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). , 1997, Blood.
[14] M. Vignetti,et al. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. , 1996, Bone marrow transplantation.
[15] M. Labopin,et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). , 1996, Bone marrow transplantation.
[16] V. Gómez-García de Soria,et al. Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome. , 1996, Bone marrow transplantation.
[17] J. Klein,et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. , 1996, Leukemia.
[18] F. Mandelli,et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.
[19] R. Storb,et al. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. , 1994, Bone marrow transplantation.
[20] P. Fenaux,et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Sanz,et al. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] T. Lister,et al. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen‐year period , 1993, British journal of haematology.
[23] H. Tilly,et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. , 1993, Leukemia.
[24] M. Labopin,et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe : further evidence of the role of marrow purging by mafosfamide , 1991 .
[25] R. Marcus,et al. Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Niland,et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H. Gralnick,et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.
[28] P. Fenaux,et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. , 1991, Blood.
[29] R. Holle,et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. , 1991, Bone marrow transplantation.
[30] F. Mandelli,et al. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. , 1990, Blood.
[31] G. Meloni,et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. , 1990, Blood.
[32] K. Sullivan,et al. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. , 1987, Bone marrow transplantation.
[33] O. Colvin,et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. , 1986, The New England journal of medicine.
[34] B. Coiffier,et al. Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias. , 1986, Cancer treatment reports.
[35] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[36] D. Catovsky,et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[37] J. Karp,et al. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. , 1984, Blood.
[38] J. Karp,et al. Long chemotherapy‐free remissions after single‐cycle timed‐sequential chemotherapy for acute myelocytic leukemia , 1980, Cancer.
[39] J. Karp,et al. A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation. , 1980, Blood.
[40] H. Preisler. Failure of remission induction in acute myelocytic leukemia. , 1978, Medical and pediatric oncology.
[41] C. Spurr,et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. , 1968, Blood.